相关实验视频
Updated: Jun 23, 2025

09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.5K
在患有与膜蛋白相关的神经退行症的患者中使用elamipretide的扩展访问
Jorge Patino1, Anna Haertling Clearman2, Lindsey Miller2
1Department of Neurology University of Texas McGovern Medical School Houston Texas USA.
Clinical case reports
|June 26, 2024
概括
埃拉米普雷提德治疗改善了17岁的膜蛋白相关神经退行症患者的症状和功能测试. 这为管理这种罕见的神经疾病提供了希望.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜蛋白相关的神经退行是一种罕见的,进展性神经系统疾病.
- 目前的治疗选择有限,重点是支持性护理.
研究的目的:
- 报告患有与膜蛋白相关的神经退行症的患者用elamipretide治疗的临床结果.
- 评估elamipretide在改善神经症状和功能移动性方面的疗效.
主要方法:
- 一个17岁的女性患者的病例报告,遗传确认了与膜蛋白相关的神经退行症.
- 开始治疗elamipretide,并进行了临床评估.
主要成果:
- 患者在肌痛性关节障碍,消化障碍和步态方面经历了症状改善.
- 在6分钟的步行测试和5次的坐立测试中观察到客观的功能收益.
结论:
- 埃拉米普雷提德在这种患有膜蛋白相关神经退行症的患者中显示出积极的治疗效果.
- 需要进一步研究以拉米普雷提德作为这种疾病的治疗方法.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
317
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
317
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
285
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
285
Antiepileptic Drugs: Potassium Channel Activators
168
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
168
ER Retrieval Pathway
3.8K
In the secretory pathway, vesicles transport proteins from one cellular compartment to another in forward transport to deliver the protein to its correct location. Occasionally, misfolded proteins and incorrect proteins escape their original compartments, and a retrieval pathway is used to return the escaped proteins to their original compartment.
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
3.8K
Insertion of Multi-pass Transmembrane Proteins in the RER
8.0K
The rough ER membrane synthesizes, assembles, and embeds transmembrane proteins in diverse topologies. These proteins function as transporters or channels and can remain in the ER membrane or are sent to the Golgi complex, lysosome, and cell membrane.
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
8.0K
Tail-anchoring of Proteins in the ER Membrane
3.1K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.1K

